aTyr Pharma Inc (LIFE)
3.00
+0.15 (+5.26%)
USD |
NASDAQ |
Sep 30, 16:00
2.99
-0.01 (-0.33%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 85.88M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -66.96% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.312 |
| Price to Book Value | 0.9912 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.44% |
News
Headline
Wire
Time (ET)
Yahoo
09/29 08:00
MT Newswires
09/27 11:20
Yahoo
09/27 08:00
Yahoo
09/16 08:35
Yahoo
09/13 08:00
Globe Newswire
09/09 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/10/2022* | -- | Results | Q3 2022 | -- | -0.46 | -- | |
| 11/10/2022* | 17:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/15/2022 | -- | Results | Q2 2022 | -0.44 | -0.38 | -15.18% | |
| 08/15/2022 | 17:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/09/2022 | -- | Results | Q1 2022 | -0.44 | -0.33 | -32.66% | |
| 05/09/2022 | 17:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 03/14/2022 | -- | Results | Q4 2021 | -0.31 | -0.28 | -9.41% | |
| 03/14/2022 | 17:00 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. It's lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. It is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. |
| URL | https://www.atyrpharma.com |
| Investor Relations URL | https://investors.atyrpharma.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Nov. 10, 2022 (est.) |
| Last Earnings Release | Aug. 15, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of September 30, 2022.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 41.33M |
| Net Income (TTM) | -40.80M |
| Total Assets (Quarterly) | 96.02M |
| Total Liabilities (Quarterly) | 9.558M |
| Shareholders Equity (Quarterly) | 86.64M |
| Cash from Operations (TTM) | -38.79M |
| Cash from Investing (TTM) | -39.60M |
| Cash from Financing (TTM) | 85.42M |
Ratings
Profile
Edit
| aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. It's lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. It is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. |
| URL | https://www.atyrpharma.com |
| Investor Relations URL | https://investors.atyrpharma.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Nov. 10, 2022 (est.) |
| Last Earnings Release | Aug. 15, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| LIFE Tweets |